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Peart Disease Risk Determines
enopausal Age Rather Than the Reverse
elen S. Kok, MD, PHD,*†‡ Kristel M. van Asselt, MD, PHD,*†‡ Yvonne T. van der Schouw, PHD,*
ngeborg van der Tweel, PHD,§ Petra H. M. Peeters, MD, PHD,* Peter W. F. Wilson, MD, PHD,
eter L. Pearson, MD, PHD,‡ Diederick E. Grobbee, MD, PHD*
trecht, the Netherlands; and Boston, Massachusetts
OBJECTIVES The purpose of this study was to investigate whether a harmful cardiovascular risk profile
accelerates menopause.
BACKGROUND Women with an early menopause are at an increased risk of cardiovascular disease. Although
increased cardiovascular risk has been proposed as consequence of menopause, the alternative
hypothesis, that increased premenopausal cardiovascular risk promotes early menopause,
needs to be examined.
METHODS We used data from the Framingham Heart Study cohort. This study started in 1948 and has
followed up participants biennially since then. Women who were premenopausal at study
entry and who reached natural menopause after at least two examination rounds were
included in the study (n  695). Premenopausal age-independent levels of serum total
cholesterol, relative weight, blood pressure, and Framingham risk score were determined, as
well as premenopausal changes in cholesterol, body weight, and blood pressure.
RESULTS A higher premenopausal serum total cholesterol level was statistically significantly associated
with an earlier age at menopause, as were increases in total serum cholesterol, relative weight,
and blood pressure in the premenopausal period. A decrease in total serum cholesterol during
premenopause was statistically significantly associated with later age at menopause. Decreas-
ing blood pressure was associated with a later menopausal age, but this association was not
statistically significant. A decrease in relative weight was associated with a significant earlier
age at menopause. Each 1% higher premenopausal Framingham risk score was associated
with a decrease in menopausal age of 1.8 years (95% confidence interval 2.72 to 0.92).
CONCLUSIONS The findings support the view that heart disease risk determines age at menopause. This offers
a novel explanation for the inconsistent findings on cardiovascular disease rate and its
relationship to menopausal age and effects of hormone replacement therapy. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.066Cardiol 2006;47:1976–83) © 2006 by the American College of Cardiology Foundation
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tomen with an early menopause are at an increased risk of
ardiovascular disease (1,2). Cardiovascular risk factor
hanges occurring with menopause have been considered
he biological mechanism (3). There is evidence to show
hat menopause is accompanied by unfavorable levels of
everal cardiovascular risk factors (4,5). Deprivation of
See page 1984
ndogenous estrogen is assumed to be a crucial factor in the
xplanation of this change to a less favorable risk profile, but
onflicting results have been published, leaving the role of
sudden) estrogen deprivation under debate (6,7). Observa-
ional studies have consistently reported beneficial effects of
strogen intake after menopause on cardiovascular disease
isk (8). However, large-scale primary (Women’s Health
nitiative) and secondary (Heart and Estrogen-Progestin
eplacement Study) prevention trials assessing the effect of
ormonal replacement therapy on cardiovascular events
From the *Julius Center for Health Sciences and Primary Care, the †Department
f Reproductive Medicine, and the ‡Department of Medical Genetics, University
edical Center, and the §Center for Biostatistics, Utrecht University, Utrecht, the
etherlands; and the The Framingham Heart Study, Boston-University School of
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Manuscript received April 25, 2005; revised manuscript received November 7,
005, accepted December 21, 2005.ould not show a positive effect (9,10). These findings not
nly cast doubt on the benefits of postmenopausal estrogen
epletion therapy, but also question the supposed causality
f the association between menopause and increased risk for
ardiovascular disease, forcing consideration of other
ypotheses.
Ovaries are highly vascularized organs, and subsequent
schemic damage to the ovaries may induce early meno-
ause. In more general terms, although atherosclerosis
rogression has been proposed to be a consequence of
enopause, the alternative scenario that atherosclerosis
romotes early menopause merits further investigation. We
et out to investigate the role of premenopausal cardiovas-
ular risk factors on early ovarian failure, characterized by
arly age at menopause.
ETHODS
tudy population. The Framingham Heart Study is a
ong-term prospective study of cardiovascular disease. The
ampling procedure, design, and methods of the study have
een amply described (11,12). The participants eligible for
his study consisted of 2,873 women age 29 to 62 years at
he beginning of the study in 1948, and participants have
een examined biennially since then.
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May 16, 2006:1976–83 Heart Disease Risk Factors and Menopausal AgeTo allow investigation of the premenopausal change in
he variables, data from at least two examinations are
equired. Data on menopausal status and type of menopause
ere first reported in examination 2, and then at each
ubsequent examination. At each examination, the date of
he last menstrual period was recorded. To be classified as
aving had a natural menopause at a given examination, a
oman must have had complete cessation of menses for at
east one year before that examination.
Women classified as menopausal at examination 2 (n 
,653) were excluded because of insufficient premenopausal
ata on cardiovascular risk factors. Women were excluded
rom the sample if they experienced an artificial menopause,
.e., surgical, chemical, or radiological (n  258), or were
ost to follow-up before reaching menopause (n 230). For
he remaining women the age at menopause was determined
t the time of clinical visits, and an unknown age at
enopause resulted in exclusion (n  37). From examina-
ion 2 through 13, a total of 695 (57% of those eligible)
omen reached natural menopause.
eterminants. Cardiovascular risk factors examined in this
tudy are: 1) premenopausal total serum cholesterol level,
) premenopausal change in total serum cholesterol,
) premenopausal relative weight, 4) premenopausal change
n relative weight, 5) premenopausal blood pressure, 6) pre-
enopausal change in blood pressure, and 7) premenopausal
ramingham risk score, representing a 10-year probability
f coronary heart disease.
Total serum cholesterol was measured by the Abell-
endall method in mg/dl (13). The Framingham relative
eight is the ratio of each individual’s body weight to the
moothed median weight for a person in that sex and height
roup multiplied by 100 (4). The risk score represents the
stimate of total coronary heart disease risk (%) over the
ourse of 10 years for persons without known heart disease
nd was determined by using the equations that are given in
he Appendix (14).
ata analysis. Because of differences in age at enrollment
n the study and at natural menopause, the number of
xaminations and corresponding age differed among partic-
pants. This caused variation in the number of available
easurements of cholesterol, relative weight, and systolic
nd diastolic blood pressure per woman. A three-step
ethod was used to make optimal use of the abundance of
ongitudinal data, to correct for age at the measurements,
nd to assess the effects of both premenopausal risk factors
nd change in risk factors on age at menopause.
First, a linear regression analysis was conducted separately
or each woman relating cholesterol levels to chronological
Abbreviations and Acronyms
CI  confidence interval
HDL  high-density lipoproteinge. For this purpose, we used cholesterol levels deter- ained at 2-year intervals preceding menopause with a
aximum of 20 years. Consequently, the regression
quations are based on 2 to 10 measurements. The
esulting regression-coefficient (b) represents the individ-
al change in cholesterol level with advancing age. From
he individual regression function, premenopausal cho-
esterol levels were estimated at age 43 years, which
epresents the mean age of cholesterol measurements for
ll women. Using the mean age prevents the need for
xtensive estimation of values by extrapolation. Women
ho reached menopause before the age of 43 years were
ot excluded from the analyses (n  23).
The second step involved linear regression analyses with
ge at menopause as the dependent variable and the age-
djusted estimated cholesterol level (at age 43 years) as the
ndependent variable. Finally, to assess the effect of choles-
erol change during the premenopausal period, three cate-
ories were created: 1) women with decreasing levels of
holesterol with advancing age (b 0.5); 2) women with
table cholesterol levels with advancing age (0.5  b
0.5); and 3) women with increasing cholesterol levels with
dvancing age (b 0.5). To determine the size of the effect
f increasing and decreasing levels within a category, linear
egression analysis was conducted using b as a continuous,
ndependent variable. The same three-step procedure was
ollowed for relative weight, systolic blood pressure, and
iastolic blood pressure.
To control for potential confounding in these analyses,
djustments were made for smoking status. Smoking status
yes or no) was preferably determined at the examination as
lose to menopause as possible.
In all analyses for total serum cholesterol level, women
ere excluded if they reported use of cholesterol-lowering
rugs. Similarly, women who reported using antihyperten-
ive drugs were excluded from all analyses of systolic and
iastolic blood pressure.
The Framingham risk score includes age, total serum
holesterol, high-density lipoprotein (HDL) cholesterol,
moking status, diabetes, and blood pressure, and interac-
ions between these factors. In the equations for calculating
he score a quadratic term for age is incorporated, and
herefore no linear relation between the Framingham risk
core and age can be assumed. Thus, the effect of premeno-
ausal change in heart disease risk reflected in the Framing-
am risk score cannot be assessed. The actual premeno-
ausal 10-year cardiovascular risk according to the
ramingham risk score can, however, be determined validly
nd was computed at age 35 years. About half of the women
n the study population (n 310) were included at or before
5 years of age. The HDL cholesterol level was not available
ecause this was not included in the earliest examinations.
o determine the individual scores, all women were as-
igned a normal HDL cholesterol value that corresponds
ith 0 points for this factor. The equations estimate
oronary heart disease risk over 10 years. Linear regression
nalysis was conducted with risk as an independent variable
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Heart Disease Risk Factors and Menopausal Age May 16, 2006:1976–83nd age at menopause as a dependent variable. All analyses
ere performed using SPSS 11 for Windows (SPSS Inc.,
hicago, Illinois).
ESULTS
or our study population (n  695), the age at study entry
anged from 34 to 55 years (mean 45.5 years, standard
eviation 3.3 years). Age at menopause ranged from 38 to
8 years (mean 49.9 years, standard deviation 3.2 years)
Fig. 1). Cardiovascular risk factors at the time of meno-
ause are shown in Table 1.
moking. Forty-two percent of the women reported smok-
ng during the period preceding menopause, and the smok-
rs experienced menopause on average 1.6 years earlier than
onsmokers (95% CI 1.1 to 2.1).
holesterol. Five women used cholesterol-lowering drugs
n the premenopausal period and were excluded from the
nalyses. Of the remaining 690 women, 648 women had
ata on cholesterol level from at least two examinations.
he range of total serum cholesterol level of all premeno-
ausal cholesterol measurements was 119 to 490 mg/dl (3.1
Figure 1. Distribution of age at menopause.
able 1. Mean Values of Cardiovascular Risk Factors at the
ime of Menopause
Risk Factor Mean SD
holesterol (mg/dl) 248.5 45.2
iastolic blood pressure (mm Hg) 83.6 14.4
ystolic blood pressure (mm Hg) 127.3 22.0
ramingham relative weight 101.4 15.8o 12.7 mmol/l). In six women, the age-adjusted estimated
holesterol level at age 43 years fell out of the range of
riginal cholesterol levels, and they were excluded from
urther analyses. The mean number of examinations for the
emaining 642 women was 4.9 (standard deviation 1.7). The
ean estimated cholesterol level was 220.6 mg/dl (standard
eviation 38.6 mg/dl) (5.7 mmol/l, standard deviation 1.0
mol/l).
Adjusted for smoking, each 20-mg/dl (0.52-mmol/l)
igher estimated premenopausal cholesterol level was asso-
iated with a 0.14-year earlier occurrence of menopause
95% CI 0.26 to 0.00) (Table 2). Within the subgroup
f women with increasing levels of cholesterol, adjusted for
moking, each 20-mg/dl increase in total serum cholesterol
as associated with a 2.60-year earlier occurrence of meno-
ause (95% CI 0.06 to 1.14). Within the subgroup of
omen with decreasing levels of cholesterol, adjusted for
moking, each 20-mg/dl decrease in total serum cholesterol
as associated with a 4.16-year later age at menopause (95%
I 0.08 to 8.24) (Table 3).
elative weight. For 656 women at least two premeno-
ausal relative weight measures were available, and pre-
enopausal age-independent estimated relative weight was
omputed at 43 years of age. The mean number of exami-
ations available per woman was 5.9 (standard deviation
.1). The mean estimated relative weight was 99.1% (stan-
ard deviation 15.7%). Adjusted for smoking status, a 5%
igher premenopausal relative weight was associated with a
.07-year (95% CI0.02 to 0.17) higher age at menopause,
lthough this was not statistically significant (Table 2).
ithin the group of women who gained weight, menopause
ccurred 7.15 years earlier per 5% increase in relative weight
95% CI 12.00 to 2.33) after adjustment for smoking.
n the group of women who became leaner, adjusted for
moking, each 5% decrease in relative weight was associated
ith a 3.54-year earlier age at menopause (95% CI6.20 to
0.88) (Table 3).
lood pressure. After exclusion of women who used anti-
ypertensive drugs (n  92), 561 women had two or more
lood pressure measurements, and premenopausal age-
ndependent systolic and diastolic blood pressure was com-
uted at age 43 years. Five women were excluded because
he estimated values fell out of the range of original blood
ressure values, leaving 556 women for the analyses. The
ean number of examinations available per woman was 5.4
standard deviation 2.0). The mean estimated systolic blood
ressure was 121.4 mm Hg (standard deviation 14.1 mm
g), and the mean diastolic blood pressure was 77.9 mm
g (standard deviation 10.0 mm Hg).
ystolic blood pressure. Adjusted for smoking, estimated
ystolic blood pressure level was not statistically significantly
ssociated with age at menopause (Table 2). In the group of
omen with increasing levels of systolic blood pressure
uring the premenopausal period, each 10-mm Hg increase
s associated with a 3.45-year earlier menopause (95% CI5.42 to 1.49) when adjusted for smoking. Among the
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May 16, 2006:1976–83 Heart Disease Risk Factors and Menopausal Ageomen with decreasing levels of systolic blood pressure,
ach 10-mm Hg decrease is associated with a 1.53-year later
ge at menopause (95% CI 0.00 to 3.06) after adjustment
or smoking (Table 3).
iastolic blood pressure. Adjusted for smoking, estimated
iastolic blood pressure level was not statistically significantly
ssociated with age at menopause (Table 2). Women with
ncreasing levels of diastolic blood pressure had a 7.38-year
arlier occurrence of menopause with each 10-mm Hg in-
rease (95% CI 10.78 to 3.98) after adjusting for
moking. In the group of women with decreasing levels of
iastolic blood pressure, menopause was reached 2.48 years
95% CI 0.53 to 5.48) later for each 10-mm Hg increase
hen adjusted for smoking (Table 3).
ramingham risk score. The Framingham risk score was
etermined at age 35 years. For 248 women of the 310
omen eligible for this analysis, all variables (except HDL
holesterol) were available to determine a Framingham risk
core. The risk ranged from 0.43% to 2.80% with a mean of
.1% (standard deviation 0.46%). A 1% higher 10-year risk
or coronary heart disease was associated with a significantly
ower age at menopause, a mean reduction in menopausal
ge of 1.8 years (95% CI 2.72 to 0.92). Considering the
isk range in this population, the effect on menopausal age
able 2. Relationship Between Premenopausal Cardiovascular Ri
Determinant n
Crude Change in Ag
at Menopause (yrs)
remenopausal cholesterol level
(per 20 mg/dl* higher level)
642 0.20
remenopausal relative weight
(per 5% higher relative weight)
656 0.09
remenopausal systolic blood pressure
(per 10 mm Hg higher level)
556 0.14
remenopausal diastolic blood pressure
(per 10 mm Hg higher level)
560 0.09
20 mg/dl  0.5 mmol/l.
CI  confidence interval.
able 3. Effect of Premenopausal Increasing or Decreasing Chole
Subgroup n
Crude Change in Age
at Menopause (yrs)
holesterol
Increasing cholesterol level 514 2.48 yrs per 20 mg/dl* increase
Decreasing cholesterol level 94 3.44 yrs per 20 mg/dl* decrease
elative weight
Increasing relative weight 274 6.60 yrs per 5% increase
Decreasing relative weight 90 3.36 yrs per 5% decrease
ystolic blood pressure
Increase in systolic blood
pressure
273 3.00 yrs per 10 mm Hg increase
Decrease in systolic blood
pressure
135 1.74 yrs per 10 mm Hg decrease
iastolic blood pressure
Increase in diastolic blood
pressure
229 7.01 yrs per 10 mm Hg increase
Decrease in diastolic blood
pressure
117 2.98 yrs per 10 mm Hg decrease20 mg/dl  0.5 mmol/l.
CI  confidence interval.ould amount to more than four years in women with the
ighest risk.
ISCUSSION
he results of this analysis from data on female participants
n the Framingham Heart Study show that levels of pre-
enopausal risk factors for cardiovascular disease affect the
ge at menopause. This offers an alternative explanation for
he seemingly adverse effect of early menopausal transition
n cardiovascular disease risk. Current views on the rela-
ionship between menopause and cardiovascular risk assume
strogen depletion to be a causal factor in the increase in
ardiovascular risk. Conversely, however, menopause may
ot induce a change in cardiovascular risk profile, but a
oman’s atherosclerotic status may influence age at onset of
enopause. Consequently, the observation that women
ith an early age at menopause are at a higher risk for
ardiovascular disease might, in part, reflect an unfavorable
isk profile present before menopause. These results are not
ecessarily in conflict with the possibility that estrogen
epletion during and after menopause has a role in the
hange in cardiovascular risk; both hypotheses are not
utually exclusive.
d Age at Menopause by Linear Regression Analysis
95% CI
Adjusted for Smoking Change
in Age at Menopause (yrs) 95% CI
0.32 to 0.06 0.14 0.26 to 0.00
0.02 to 0.15 0.07 0.02 to 0.17
0.04 to 0.32 0.12 0.05 to 0.31
0.37 to 0.19 0.11 0.38 to 0.15
l Level, Relative Weight, and Blood Pressure
95% CI
Adjusted for Smoking Change
in Age at Menopause (yrs) 95% CI
3.88 to 1.08 2.60 yrs per 20 mg/dl increase 4.06 to 1.14
0.14 to 7.02 4.16 yrs per 20 mg/dl decrease 0.08 to 8.24
11.25 to 1.90 7.15 yrs per 5% decrease 12.00 to 2.33
6.10 to 0.60 3.54 yrs per 5% increase 6.20 to 0.88
5.06 to 0.96 3.45 yrs per 10 mm Hg increase 5.42 to 1.49
0.19 to 3.30 1.53 yrs per 10 mm Hg decrease 0.00 to 3.06
10.49 to 3.54 7.38 yrs per 10 mm Hg increase 10.78 to 3.98
0.11 to 6.06 2.48 yrs per 10 mm Hg decrease 0.53 to 5.48sk an
estero







l
i
p
s
a
t
j
r
d
i
a
t
a
r
fi
d
m
n
c
w
N
c
n
a
t
t
r
(
e
e
c
s
m
c
F
m
F
m
1980 Kok et al. JACC Vol. 47, No. 10, 2006
Heart Disease Risk Factors and Menopausal Age May 16, 2006:1976–83It should be emphasized that premenopausal cholesterol
evel as well as premenopausal relative weight are age-
ndependent estimated values computed from all available
remenopausal measurements for an individual. An as-
umption of the linearity of the relationships between age
nd cholesterol level and age and relative weight, respec-
ively, was made. Based on Figures 2 and 3, this seems
ustified, for both associations the R2 value for the linear
elationship was 97%, and the linear terms were significantly
ifferent from zero (p  0.001). Moreover, these results are
n line with those reported in Figure 1 by van Beresteijn et
l. (15).
The strength of the methods used for analysis relates to
he issue of confounding by chronological age while using
ll data available for each woman. When cholesterol level,
elative weight, and blood pressure were determined at a
xed number of years before menopause for all women,
ifferences in chronological age at time of measurement
ight have confounded the results.
igure 2. Association of years before menopause (MP0  menopause; M
enopause, and so on) and mean cholesterol level in mg/dl.igure 3. Association of years before menopause (MP0  menopause; MP_1 
enopause, and so on) and mean relative weight.A potential drawback of the method as applied is the
eed for extrapolation of the regression line for age and
holesterol and for age and relative weight for part of the
omen to determine their estimated value at age 43 years.
o selection of age could fully prevent extrapolation, but the
hoice of this age resulted in the least extrapolations
ecessary, i.e., 8.7% for cholesterol, 2.1% for relative weight,
nd 5.8% for blood pressure. In our opinion, these limita-
ions are easily outweighed by the advantage of separating
he effects of level and change without confounding by age.
Concerns have been expressed regarding the reliability of
eported age at menopause, especially after a long follow-up
16,17). In the current study, as a result of the frequent
xaminations, the time interval is always small, making
rrors in reported menopausal ages unlikely. A point of
oncern, however, is to what extent menopause can really be
een as a distinct event at a discrete point in time. Natural
enopause does not ordinarily occur abruptly, and the
hanges in hormonal status associated with it could involve
one examination before menopause; MP_2  two examinations beforeP_1 one examination before menopause; MP_2  two examinations before
a
T
o
c
t
l
p
c
m
t
t
p
s
r
y
a
r
a
r
c
e
u
y
H
a
d
t
p
c
s
t
m
h
w
c
(
r
t
b
o
d
i
f
W
d
e
o
r
T
k
b
p
f
M
t
p
(
e
H
r
s
l
e
w
o
o
t
t
s
d
i
l
d
s
a
p
c
t
c
S
t
a
t
w
o
g
t
q
m
s
d
s
n
H
m
t
w
a
a
i
m
b
1981JACC Vol. 47, No. 10, 2006 Kok et al.
May 16, 2006:1976–83 Heart Disease Risk Factors and Menopausal Agedynamic process of progressive decline in ovarian function.
herefore, the data included in the analyses that were
btained during the years directly before the reported
essation of menses may not be completely independent of
he effect of the gradual hormonal changes preceding the
ast menstruation. Several studies have shown that the
erimenopause, characterized by an irregular menstrual
ycle pattern, lasts on average four years (18–20). Further-
ore, it has been shown that estradiol levels remain rela-
ively unchanged until the onset of the menopausal transi-
ion and are usually well preserved until the late
erimenopause, presumably in response to elevated follicle-
timulating hormone levels (21,22). Burger et al. (23)
eported that estradiol levels begin to decline about two
ears before the last menstrual period, decrease most rapidly
round that time, and plateau two years later. Because our
esults are based on a mean premenopausal period of
pproximately 10 years for each woman, we argue that our
esults are likely to be unaffected by menopause itself. To
onfirm this assumption, we reanalyzed the data while
xcluding the examination preceding menopause, thus eval-
ating data until two years before menopause. These anal-
ses yielded similar results as those presented using all data.
owever, most of the studies that look at premenopausal
nd peri-menopausal hormonal levels have evaluated estra-
iol levels at certain fixed time points in the cycle, a design
hat does not capture dynamic changes in levels. Premeno-
ausally, hormonal levels can fluctuate strikingly within the
ycle and from cycle to cycle with intermittent estrogen
urges. Therefore, we cannot fully exclude the possibility
hat the worsening of risk factors that seems to relate to
enopausal age is not a consequence of changes in the
ormonal environment before cessation of menstruation.
Although there are several studies suggesting that over-
eight decelerates menopause, there are also studies indi-
ating no effect of body weight on timing of menopause
24–26). These conflicting results might be a result of
esidual confounding for example by age. In the one article
hat was particularly able to exclude confounding by age (27)
y selection of women born in one week in 1946, no effect
f body weight was found on the timing of menopause.
It is well known that overweight increases cardiovascular
isease risk, moreover, several observational as well as
ntervention studies have shown that cardiovascular risk
actors rapidly improve when weight is reduced (28,29).
eight loss would therefore be expected to result in
ecreased excess mortality associated with overweight; how-
ver, the opposite has been found in several large epidemi-
logic studies (30–33). In particular cardiovascular disease
emains the main cause of mortality in people losing weight.
he biological mechanism behind this phenomenon is not
nown; apparently weight loss is not only associated with
eneficial effects, such as improved cardiovascular risk factor
rofile, but also with some harmful effects, of which loss of
at-free mass has been suggested to be one factor (34). paybe these harmful effects also accelerate menopause, but
his is still theoretical.
Smoking is known to affect menopausal age, and meno-
ause occurs 0.8 to 2 years earlier in smoking women
35,36). Explanations have been sought in an antiestrogenic
ffect of nicotine and a toxic effect on the follicles (37).
owever, theoretically, smoking could promote atheroscle-
osis of the ovarian arteries and ischemia. In that case,
moking might have been better captured by adjusting for
ifetime smoking exposure, or in this case, by smoking
xposure at enrollment in the Framingham study. However,
e recently found that only smoking at or around the onset
f menopause affects the timing of menopause (38). Previ-
us smoking does not affect the onset of menopause;
herefore, it is justified to study smoking behavior only at
he last examination before menopause.
Blood vessel stiffness increases over time, whereas dia-
tolic blood pressure tends to decrease. The women with
ecreasing diastolic pressure levels probably consist at least
n part of those with “hardening of the arteries.” This is a
ikely explanation for the fact that “beneficial” changes in
iastolic blood pressure did not result in a statistically
ignificant increase in menopausal age.
Cohort studies investigating menopause or menopausal
ge and cardiovascular disease risk have compared premeno-
ausal levels or premenopausal trends of risk factors, such as
holesterol or body weight, with postmenopausal levels or
rends. Alternatively, risk factor levels of fertile women were
ompared with levels of postmenopausal women (4,15,39).
till, doubt remains regarding whether menopause worsens
he cardiovascular risk patterns (40).
The inevitable consequence of cross-sectional studies on
ge-matched premenopausal and postmenopausal women is
hat women with a later age at menopause are compared
ith women with an earlier age at menopause. In view of
ur hypothesis, the observation that the postmenopausal
roup has a less favorable risk profile may simply reflect that
hese are women with an earlier menopause as a conse-
uence of a worse cardiovascular risk profile.
Recently, we have shown that the factor V Leiden
utation is associated with an earlier age at menopause,
upporting the idea of a vascular mechanism involved in
etermining age at menopause (41).
Although the cardiovascular risk profile appears to be a
trong determinant of age at menopause, the mechanism is
ot apparent. Atherosclerosis is a generalized process (42).
owever, the idea that atherosclerotic changes in the
icrovascularization of the ovaries accelerate ovarian aging
hrough decreased perfusion may be too simplistic. Body
eight, cholesterol level, diabetes mellitus, blood pressure,
nd smoking have negative vascular effects, but may also
ffect the endocrine system, which in turn could have an
mpact on menopausal age. Because several of the factors
entioned earlier are included in definitions of the meta-
olic syndrome (43), it is possible that insulin resistance
artly determines when menopause occurs. Hyperinsulin-
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o estrogens in plasma, and this process might play a role
44,45). No insulin or gonadal hormone levels are available
or Framingham women before the time of menopause, but
tudies of insulin resistance and sensitivity in premenopausal
omen are possible in future investigations.
In an alternative hypothesis, early natural menopause may
e interpreted as a sign of accelerated general aging. Cardio-
ascular risk is known to increase with age. A relatively
ccelerated biologic aging would then be reflected by both
arly menopause and an increased risk for cardiovascular
isease.
In conclusion, our results provide evidence for the view
hat atherosclerosis risk determines age at menopause rather
han the reverse. This provides a novel explanation for the
nconsistent findings of cardiovascular disease rate and its
elationship to menopausal age and the effects of hormonal
eplacement therapy.
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PPENDIX
or the calculation of the Framingham risk score, please see
he online version of this article.
